Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post Renal Transplantation Clear all
Completed Phase 4 Interventional Results available

Surgeon Infiltration QL Block Comparison

NCT03496610
View directory record Official record
Conditions
Quadratus Lumborum Block, Surgical Wound Infiltration
Interventions
Liposomal Bupivicaine, QL Block
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 13, 2026, 9:33 PM EDT
Terminated Not applicable Interventional Results available

Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation

NCT03607500
View directory record Official record
Conditions
Kidney Transplant; Complications, Glomerular Disease, Weight Gain, Kidney Transplant
Interventions
caloric intake reduction
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 4 Interventional Results available

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456
View directory record Official record
Conditions
Influenza, Human, Transplantation Infection
Interventions
influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

NCT03762473
View directory record Official record
Conditions
Renal Transplant Infection
Interventions
Study Group, Control Group
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 13, 2026, 9:33 PM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

NCT02235857
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
LIPOSORBER® LA-15 System
Device
Lead sponsor
Kaneka Medical America LLC
Industry
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • Wilmington, Delaware + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Terminated Not applicable Interventional

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

NCT00579592
View directory record Official record
Conditions
Acute Rejection, Renal Transplantation
Interventions
Campath-1H, rituximab, myfortic
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 13, 2026, 9:33 PM EDT
Completed No phase listed Observational

Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation

NCT04258891
View directory record Official record
Conditions
Kidney Transplant Failure
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2004 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

NCT05508009
View directory record Official record
Conditions
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Drug · Radiation · Device + 1 more
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 2 Interventional

VEL-101 to Prevent Rejection After Kidney Transplantation

NCT07290777
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Tacrolimus (TAC), VEL-101
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 3 Interventional

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

NCT06407232
View directory record Official record
Conditions
Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
Interventions
Letermovir
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation

NCT02417870
View directory record Official record
Conditions
Kidney Transplantation
Interventions
aldesleukin
Biological
Lead sponsor
Anil K. Chandraker, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients

NCT03765203
View directory record Official record
Conditions
Transplant;Failure,Kidney
Interventions
Natera KidneyScan, Clinical Performance and Value Vignettes
Diagnostic Test · Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Video Education and Behaviour Contract to Optimize Adherence in Renal Transplants

NCT03540121
View directory record Official record
Conditions
Kidney Transplantation, Medication Adherence
Interventions
Video education + adherence contract
Behavioral
Lead sponsor
University of Saskatchewan
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 13, 2026, 9:33 PM EDT
Recruiting Phase 3 Interventional

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798
View directory record Official record
Conditions
Delayed Graft Function, DGF, Kidney Transplant
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II

NCT02003469
View directory record Official record
Conditions
Hypertension
Interventions
Ambulatory Blood Pressure Monitoring
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 13, 2026, 9:33 PM EDT
Not listed No phase listed Observational

Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation

NCT04226859
View directory record Official record
Conditions
Kidney Transplant Failure, Kidney Function Issue
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2000 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 13, 2026, 9:33 PM EDT
Completed No phase listed Observational

Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM

NCT02070315
View directory record Official record
Conditions
Liver Disease, Heart Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Not yet recruiting Not applicable Interventional

AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function

NCT05432765
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Phenotypic Personalized Medicine Dosing, Standard of Care Dosing
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Bone Mass and Strength After Kidney Transplantation

NCT02224144
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation, Bone Loss, Fractures, Vascular Calcifications
Interventions
Vitamin D3, Calcitriol, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 13, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 13, 2026, 9:33 PM EDT